Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting
- SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton's tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST) on Monday, December 11, 2023.
- 12/04/2023
|
New Strong Buy Stocks for October 26th
- GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
- 10/26/2023
|
Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround
- Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 10/18/2023
|
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.90 per share a year ago.
- 10/12/2023
|
Nurix (NRIX) to Report Q3 Earnings: What's in Store?
- On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.
- 10/11/2023
|
Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 10/05/2023
|
Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 10/04/2023
|
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 09/28/2023
|
Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know
- Nurix Therapeutics, Inc. (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/15/2023
|
Nurix (NRIX) Stock Increases 9% in a Month: Here's Why
- The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.
- 09/11/2023
|
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?
- Nurix Therapeutics, Inc. (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 09/08/2023
|
Nurix Therapeutics to Participate in Upcoming Investor Conferences
- SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer will participate in the following conferences in September:
- 08/31/2023
|
Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to Trade
- The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 195.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 07/24/2023
|
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.01 per share a year ago.
- 07/13/2023
|
Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect?
- The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 192.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/24/2023
|
Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
- SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17th at 4:35 p.m. ET.
- 05/09/2023
|
Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should Know
- The mean of analysts' price targets for Nurix Therapeutics, Inc. (NRIX) points to a 233.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/04/2023
|
How Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94%
- The consensus price target hints at a 134.9% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 04/18/2023
|
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.95 per share a year ago.
- 04/13/2023
|
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
- Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
- 03/21/2023
|
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?
- Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 03/21/2023
|
Nurix's stock rallies on Gilead's option
- Shares of Nurix Therapeutics Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gilead Sciences Inc. GILD, -3.18% said it exercised the option to exclusively license Nurix's targeted protein degrader molecule, which is being considered as a tool to treat inflammatory conditions like rheumatoid arthritis. Per the terms, Gilead will pay $20 million upfront, with an additional $425 million in potential milestone payments.
- 03/20/2023
|
Nurix: Promising Early Data From This Protein Degrader Company
- NRIX announced early data at ASH last year. The company has a couple of major partnerships.
- 03/19/2023
|
Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
- SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will provide a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference (Virtual) on Tuesday, March 14 at 10:40 a.m. ET.
- 03/06/2023
|
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -27.94% and 65.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2023
|
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
- SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix's achievements in 2022 and major goals for 2023 at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:45 pm PT.
- 01/04/2023
|
After Plunging -15.8% in 4 Weeks, Here's Why the Trend Might Reverse for Nurix Therapeutics, Inc. (NRIX)
- Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 12/28/2022
|
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
- Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET) Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)
- 12/07/2022
|
Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 187%: Read This Before Placing a Bet
- The consensus price target hints at an 187% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/04/2022
|
Nurix Therapeutics to Participate in Upcoming Investor Conferences
- SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in the following conferences in November:
- 11/02/2022
|
Nurix: Down, But Not Out
- There are four key data catalysts, one in each of Nurix's clinical candidates, arriving through end of the year. Nurix has a strong cash position that should be sufficient to fund operations through 2024.
- 10/27/2022
|
The Top 5 Stocks Cathie Wood Bought and Sold This Week
- It has been another volatile week for Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ). Shares of ARKK recently hit a five-year low and 52-week low of $33.74.
- 10/21/2022
|
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 9.09% and 12.33%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/06/2022
|
Nurix Therapeutics, Inc. (NRIX) Moves to Buy: Rationale Behind the Upgrade
- Nurix Therapeutics, Inc. (NRIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 09/07/2022
|
Nurix Therapeutics to Participate in Upcoming Investor Conferences
- SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in the following conferences in September:
- 08/31/2022
|
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -1% and 13.36%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/07/2022
|
Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
- Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 05/31/2022
|
Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
- SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18th, 2022 at 11:00 a.m. ET.
- 05/11/2022
|
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/07/2022
|
Nurix Therapeutics to Participate in Upcoming Investor Conferences
- SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in the following conferences in March:
- 03/09/2022
|
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
- SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held from April 8-13, 2022 in New Orleans, LA.
- 03/08/2022
|
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
- SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 PM ET.
- 02/10/2022
|
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/27/2022
|
Nurix: Advancing Targeted Protein Modulation Therapies
- Nurix Therapeutics is advancing a unique therapeutic approach of targeted protein modulation. The Company's current focus is on cancer treatment and small molecule immuno-oncology agents.
- 11/21/2021
|
Why Nurix Therapeutics Stock Soared More Than 21% Wednesday
- The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.
- 10/27/2021
|
Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?
- SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%. Analyst Christopher Liu notes that Nurix presented preliminary NX-2127 pharmacokinetics/pharmacodynamics data.
- 10/27/2021
|
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Tops Revenue Estimates
- Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.52% and 17.49%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/14/2021
|
Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
- Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer
- 10/14/2021
|
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders
- SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Ms. Reinsdorf is the former executive vice president and general counsel of Johnson Controls International, and Mr. Silva is the former senior vice president, chief accounting officer at Vertex Pharmaceuticals Incorporated.
- 09/30/2021
|
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development
- SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development. Ms. Wolff brings to Nurix over 30 years of leadership experience in oncology and immunology most recently from Principia Biopharma Inc., where she served as chief development officer and formerly senior vice president of strategy and operations overseeing Principia's portfolio including BTK targeted agents. During her tenure at Principia, she successfully guided drug pipeline strategy and led many functions over time, including the company's manufacturing and technical operations, regulatory and quality, clinical operations, project and portfolio management, medical affairs, commercial and communications functions until its acquisition by Sanofi in September, 2020.
- 06/21/2021
|
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
- SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc. (formerly Seattle Genetics, Inc.) and serves as its president, chief executive officer, and chairman of the board.
- 06/01/2021
|
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
- NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease
- 05/21/2021
|
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
- On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021
- 04/13/2021
|
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
- SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET.
- 04/07/2021
|
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
- Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative
- 03/16/2021
|
Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR
- CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade
- 03/10/2021
|
Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of $31.00 per share, which includes 675,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $160.4 million.
- 03/09/2021
|
Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences
- SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix's chief executive officer, will participate and present at the following conferences in March:
- 03/09/2021
|
TransCode Therapeutics Starts $29 Million IPO Effort
- TransCode Therapeutics Starts $29 Million IPO Effort
- 03/07/2021
|
Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $31.00 per share. The public offering was upsized from the previously announced size of 4,000,000 shares of its common stock. All shares of common stock are being offered by Nurix. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $139.5 million. In addition, Nurix has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 9, 2021, subject to the satisfaction of customary closing conditions.
- 03/04/2021
|
Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock
- SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares of common stock are being offered by Nurix. In addition, Nurix intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock.
- 03/02/2021
|
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update
- First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies
- 02/16/2021
|
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
- U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
- 01/16/2021
|
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
- Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies
- 12/07/2020
|
Nurix Therapeutics to Present at Upcoming Investor Conferences
- SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will be presenting at the following healthcare investor conferences:
- 11/09/2020
|
Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition
- SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present data on its novel targeted protein degradation platform at the upcoming 5th Medicinal Chemistry & Protein Degradation Summit and preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
- 11/04/2020
|
Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors
- SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company's Board of Directors effective November 1, 2020. Dr. Tjian (“Tij”) has served as a member of our Board of Directors since November 2016. Dr. Tjian will continue to provide guidance and advice to Nurix in his new role as Chairman of Nurix's Scientific Advisory Board.
- 10/26/2020
|
CBL Properties To File For Chapter 11 | PYMNTS.com
- Mall owner CBL Properties intends to file a pre-packaged Chapter 11 bankruptcy to eliminate some $1.5 billion of debt.
- 08/20/2020
|
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
- 08/20/2020
|
Mall Owner CBL Plans to File for Bankruptcy
- One of the country’s largest mall owners, pummeled by the Covid-19 pandemic, plans to file for chapter 11 by Oct. 1 as part of debt-for-equity swap with bondholders.
- 08/19/2020
|
U.S. mall owner CBL strikes restructuring deal with lenders to slash debt
- U.S. mall owner CBL & Associates announced it has reached a restructuring agreement with debt holders in a bid to boost its balance sheet.
- 08/19/2020
|
CBL & Associates enters into restructuring support agreement with debt holders
- CBL & Associates Properties Inc. undefined said Wednesday that it has entered into a restructuring support agreement (RSA) with its debt holders, in an...
- 08/19/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
Mall REITs: Shop Till You Drop
- From bad to worse. Entering 2020 on already unstable footing following a tsunami of store closings over the past half-decade, mall REITs have been punished by the ongoing coronavirus pandemic.
- 08/18/2020
|
The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
- 08/18/2020
|
IPO Update: Kymera Therapeutics Readies $125 Million IPO
|
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 08/15/2020
|
No Deal, No Problem
- U.S. equity markets continued their seemingly relentless rally this week despite a stalemate in stimulus negotiations as an encouraging slate of employment data quelled concerns about an ebbing recovery.
- 08/08/2020
|
How Nike rejection birthed sports wear industry in Nigeria | Nairametrics
- How Nike rejection birthed sports wear industry in Nigeria Sports
- 08/08/2020
|
Kymera Therapeutics Begins U.S. IPO Effort (Private:KYTX)
- Kymera Therapeutics has filed to raise $100 million in an IPO, although the final figure may vary. The firm is advancing drug treatment candidates for skin conditions and cancers.
- 08/05/2020
|
CBL Properties to Close Its Properties on Thanksgiving Day for the Fifth Consecutive Year
- CBL Properties (NYSE:CBL) today announced that its portfolio of market-dominant regional shopping centers will remain closed on Thanksgiving Day for t
- 08/04/2020
|
CBL Properties Schedules Second Quarter 2020 Earnings Release
- CBL Properties (NYSE:CBL) today announced that the Company plans to issue its report of earnings for the second quarter 2020 after the close of market
- 08/03/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
- 07/29/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
U.S. IPO Weekly Recap: Software And SPACs Shine In A 7-IPO Week
- Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding and the largest SPAC ever Pershing Square Tontine Holdings.
- 07/25/2020
|
Brick & Mortar Retailers, Malls, Mall-REITs, and their Debts: The Whole Schmear is Coming Apart
- There’s Just No Good Way Out.
- 07/25/2020
|
Nurix Therapeutics shares slide 2.3% in trading debut
- Nurix Therapeutics Inc. shares fell 2.3% in their trading debut Friday, after pricing above the proposed price range. Nurix sold 11 million shares priced at $19 each, above a recently tweaked $17 to $18 range. Its original plan was to sell 8.8 million shares priced at $16 to $18. The shares are trading on Nasdaq, under the ticker "NRIX." JPMorgan, Piper Sandler, Stifel and Needham & Co. were underwriters on the deal. Proceeds will be used to fund clinical research and R&D, as well as for working capital and general corporate purposes. "We are a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders," the company says in its prospectus. The IPO market has been strong recently and the Renaissance IPO ETF has gained 33% in the year to date, outperforming the S&P 500 , which is down 0.7%.
- 07/24/2020
|
Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering
- SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nurix), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being offered by Nurix. The shares are expected to begin trading on The Nasdaq Global Market on July 24, 2020 under the symbol “NRIX.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $209 million. In addition, Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on July 28, 2020, subject to the satisfaction of customary closing conditions. J.P. Morgan, Piper Sandler and Stifel are acting as joint bookrunning managers for the proposed offering. Needham & Company is acting as lead manager.A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on July 23, 2020. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at Prospectus-eq_fi@jpmchase.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or via email at prospectus@psc.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or via email at syndprospectus@stifel.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.Investor Contact Janhavi Mohite Stern Investor Relations janhavi.mohite@sternir.comMedia Contact Sara Zelkovic LifeSci Communications sara@lifescicomms.com
- 07/23/2020
|
IPO Update: Nurix Therapeutics Prepares IPO Terms
- Nurix Therapeutics has filed to raise $150 million in a U.S. IPO.
- 07/21/2020
|
U.S. IPO Week Ahead: Software Provider Jamf Takes The Spotlight In A Diverse 4-IPO Week
- Four IPOs and one SPAC plan to raise $663 million in the week ahead, led by Jamf Holding. The IPO market is on a hot streak, and the IPO pipeline is filling up as filing activity remains high.
- 07/18/2020
|
Nigerian entrepreneur becomes first African woman to own a European club | Nairametrics
- A Nigerian entrepreneur has purchased Portuguese club side Lusitano Ginasio Clube, Futebol, SAD. making her the first African woman to own a club in Europe
- 07/17/2020
|
International Insurance Company of Liberia tout droit vers la liquidation judiciaire
- La Banque centrale du Libéria (CBL) a demandé l’ouverture d’une procédure de liquidation judiciaire de la compagnie d’assurance International Insurance Company of Liberia (IICL)…
- 07/07/2020
|
Measures introduced by Nigeria to ensure transparent use of the $3.4 billion IMF loan | Nairametrics
- The IMF’s financial assistance to Nigeria is to support the healthcare sector, stabilize the economy that have been impacted by the pandemic.
- 06/01/2020
|
The week investors stayed on the sidelines at Nigeria’s stock market | Nairametrics
- The week investors stayed on the sidelines at Nigeria’s stock market Business News
- 05/16/2020
|
Equities: CBN’s heterodox policies is driving domestic investors’ to the stock market. |
- The NSE data on investor participation for March 2020, total value of transactions executed at the local bourse increased by 64% m/m
- 05/07/2020
|
NNPC reduces fuel price to N108 per litre | Nairametrics
- The NNPC, has reduced the price of petrol from N113.28k per litre to N108.00k per litre representing a 4.8% drop in prices
- 05/06/2020
|
Access Bank Plc reports profit of N40.9 billion for Q1 2020 | Nairametrics
- Access Bank Plc recorded a profit after tax of N40.9 billion in the first quarter period ended March 31st, 2020. Company Profile
- 04/23/2020
|
UACN incurs N14.6 billion write down of its real estate business | Nairametrics
- UACN Nigeria posted a N9.25 billion loss from tax deductions as it incurs a N14.6 billion write down of its real estate business. Business News
- 04/20/2020
|
Moody’s affirms B2 rating for Nigeria, maintains negative outlook | Nairametrics
- American based credit rating agency, Moody’s Investors Service (Moody’s), in a report released on Wednesday, April 15, 2020,
- 04/16/2020
|
Top 10 Stockbrokers trade N391.9 billion in Q1 2020 despite bearish market |
- Despite bearish market, the top ten stockbrokers traded a total of N391.9 billion worth of shares between January and March 2020.
- 04/03/2020
|
Lessons for Nigerian fintechs, as Square gets nod for banking license | Nairametrics
- Square Financial Services Inc., is expected to launch in 2021 and will be supervised by the Federal Deposit Insurance Corp.
- 03/26/2020
|
NCC initiates second phase of sim deactivation, disables 2.2 million lines |
- About 2.2 million pre-registered or partially registered sim cards across telecommunication networks nationwide have been deactivated by NCC.
- 03/09/2020
|
What you need to know about proposed tariff review by DisCos |
- Ikeja Electric Plc is planning to increase its tariff by 50% which is expected to affect the power supply fee paid by customers.
- 02/19/2020
|
NSE holds ETF workshop, showcases broader investment opportunities | Nairametrics
- The Nigeria Stock Exchange (NSE) has disclosed that the Exchange remains committed to the development of the market
- 02/08/2020
|
Ighalo to earn N1.4 billion in six months at Manchester United |
- Despite getting a pay cut, former Super Eagles striker, Odion Ighalo, will earn about N1.4 billion in six months playing for Manchester United.
- 02/08/2020
|
FIRS boss wants to tax street traders, artisans, others |
- The Executive Chairman of FIRS, Mohammed Nami, says tax administrators need to tax street traders, artisans and other jobs in the informal sector.
- 02/06/2020
|
Barcelona overtakes Real Madrid on biggest earners’ list | Nairametrics
- Real Madrid have lost its position to Spanish League rival, Barcelona, on the list of the highest-earning football clubs in the world.
- 01/14/2020
|
CBN provides guidelines to address credit, liquidity risks, others | Nairametrics
- The Central Bank of Nigeria (CBN) has released the Nigerian Payment System Risk and Information Security Management Framework.
- 01/07/2020
|
SumoBank rebrands to SumoTrust, introduces bank account numbers | Nairametrics
- SumoBank rebrands to SumoTrust, introduces bank account numbers Company Profile
- 01/02/2020
|
Cornerstone Insurance in consolidation talk with two underwriting firms |
- Cornerstone Insurance Plc is planning to consolidate with some insurance companies ahead of the recapitalization deadline set by NAICOM.
- 12/31/2019
|
NBET boss Marilyn Amobi, sacked | Nairametrics |
- The Federal Government has sacked the Managing Director/CEO of the Nigerian Bulk Electricity Trading Plc (NBET), Dr. Marilyn Amobi.
- 12/25/2019
|
Pension funds are in trouble as inflation erodes asset values by 100% |
- Consistent depreciation in the value of Naira has eroded the value of Nigeria’s pension funds by 100% between 2012 and 2019.
- 12/11/2019
|
NUPENG, PENGASSAN support FG’s ban on fuel supply to border petrol stations | Nairametrics
- NUPENG and PENGASSAN have supported the directive of FG that the NCS should ban supply of fuel to the filling stations at border posts.
- 11/08/2019
|
World Bank’s $2.5bn loan will hurt Nigeria’s economy - LCCI | Nairametrics
- The LCCI has reacted to World Bank’s plans on disbursing another fresh loan of $2.5 billion or N767.3 billion to Nigeria.
- 09/26/2019
|
Why NUPENG threatened to ground Chevron's operations
- NUPENG has threatened to embark on industrial action against Chevron for disengaging about 500 workers, contrary to a protracted negotiation.
- 08/02/2019
|
Is sports betting gradually making Nigerian youths lazy? | Nairametrics
- There is an ongoing debate online on whether sports betting is truly an ideal business model or just means these entrepreneurs are siphoning the income of many Nigerian youths.
- 07/08/2019
|
Ajax FC's shares fall by 21% after Champions League defeat
- The Shares of AFC Ajax crashed by as much as 21 percent on Thursday, after Tottenham Hotspur's shock comeback sent the Dutch football club crashing out of Europe’s Champions League.
- 05/09/2019
|
Here's why Anambra, Kogi, and Enugu are yet to be recognised as oil-producing states
- The Department of Petroleum Resources (DRP) has ignored calls to identify Anambra, Enugu and Kogi states as oil producing regions in Nigeria
- 05/06/2019
|
BUA and Wartsila Oy of Finland sign 48MW Power project for Sokoto Line 3
- BUA Group has signed a contract with Wartsila Oy of Finland for the construction of a 48 megawatt power plant for Sokoto Cement line 3 in Sokoto State.
- 03/22/2019
|
Top 10 high-yield money market funds that beat inflation in Nigeria |
- This is where money market funds come in and play that risk management role of not losing the yield that would have, otherwise, been lost if an investor sits on his cash.
- 03/18/2019
|
Innoson Motors has entered into partnership with the Nigerian Army
- In its bid to domesticate the manufacturing of its wares, Nigeria indigenous motor manufacturing company, Innoson Motors has entered into partnership.
- 01/03/2018
|
This video of Venezuelans is enough to scare Nigerians and its neighbours | Nairametrics
- This video of Venezuelans is enough to scare Nigerians and its neighbours
- 08/14/2016
|
